Cognitive impairment and psychosis in schizophrenia: independent or linked conditions?
Open accessAbstract
Like much else regarding the pathophysiology of schizophrenia, the relationship between cognitive impairment and psychosis is far from elucidated. An undisputed observation is that they frequently co-occur. Green et al1 provide a scholarly overview of the state of knowledge in this area. However, they do not elaborate on potential reasons underlying the co-occurrence of cognitive impairment and psychosis. Much of what we observe as clinical neuroscientists is correlational. Severity of scores on the Positive and Negative Syndrome Scale (PANSS) correlate with social and vocational impairment, which in turn correlate with lifetime cumulative antipsychotic drug administration, which correlates with cardiovascular comorbidities. In health and disease, the correlation between two variables is, often, the sum of the genetic and environmental contributions to these effects. Thus, one possibility is that cognitive impairment and psychosis have a shared etiology – genetic and/or environmental. The "shared etiology" hypothesis can be tested using various methods. Environmental shared etiology is often studied in epidemiological cohort studies. Environmental factors such as obstetric complications, abuse and trauma during childhood, drug abuse, and immigration have all been reported in relation to cognitive impairment, psychosis or both2. Genetic shared etiology has been investigated using behavioral genetic methods in twins and siblings, and more recently using molecular genetic methods. Twin studies can measure the genetic correlation between two traits. A genetic correlation of 1 between trait A and B would imply that all of the additive genetic influences on trait A also impact on trait B. In one such study, the genetic correlation between schizophrenia and IQ was relatively high (r=0.75)3. However, as the correlation is only 0.75, close to half of the genetic variance in schizophrenia is actually independent of intelligence, suggesting that both traits have genes with specific effects. When specific cognitive domains rather than IQ were examined, the genetic correlations varied considerably. They were only 0.34 for tests measuring verbal knowledge and 0.79 for tests measuring working memory. In a second study, using a larger sample, the genetic correlation between schizophrenia and IQ was 0.46, suggesting that the majority of the genetic variance in schizophrenia is actually independent of intelligence3. With advances in molecular genetics, polygenic risk scores – which reflect the impact of many risk alleles of small effect – can now be used to quantify the role of directly measured risk genes for schizophrenia on specific cognitive domains. Several studies examined the relation between schizophrenia risk genes and IQ in the general population. What these studies examine is whether genetic variants associated with increased risk for schizophrenia would be associated with poorer cognitive performance. Overall, the reported correlations between the schizophrenia polygenic risk score and IQ and working memory were less than 0.1 for childhood, early and late adulthood4, 5. Similar results were observed for a range of cognitive domains6. Looking at the association from the other direction, i.e. whether genetic variants associated with poorer cognitive performance would be associated with increased risk for schizophrenia, the magnitude of associations was small as well (<1% of variance)6. Using bivariate genome-wide complex trait analysis to estimate the amount of shared genetic factors between schizophrenia risk and cognitive ability, the genetic correlation between schizophrenia and IQ was 0.2, and that between schizophrenia and working memory was 0.19. In this study, there was no evidence supporting genetic overlap between schizo-phrenia and measures of verbal knowledge or social cognition6. A second possibility is that schizophrenia and cognitive impairment co-occur because both are associated separately with a third factor. For example, studies have shown that schizophrenia is associated with structural brain abnormalities and that IQ is correlated with whole and gray brain matter volumes. It is therefore possible that the genetic correlation between schizophrenia and IQ is explained by the correlation of both traits with brain volume3. It is also possible that cognitive impairment is neither an antecedent nor an enduring consequence of schizophrenia, but it represents non-specific brain vulnerability. Since cognitive impairment characterizes almost all mental disorders, as well as neurological disorders, traumatic brain injury, and drug and alcohol abuse7, and is already present before the onset of most disorders, it seems to be a non-specific indicator of brain vulnerability or brain malfunctioning. A fourth and less investigated possibility is that schizophrenia and poor cognitive abilities co-occur coincidently. A coincidental hypothesis of psychosis and cognitive impairment would posit the following. Most co
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The use of apps requires specific skills.
“but it must be considered that the use of apps requires specific skills”
From The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: A clinical review (2020) · cites this paper as [60]
The introduction of specific smartphone apps has led to the dissemination of a SDM protocol.
“The introduction of specific smartphone apps has led to the dissemination of a SDM protocol”
From The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: A clinical review (2020) · cites this paper as [60]
It is likely that only patients with high level of personal functioning and less severe symptomatology can use these support tools, gaining a positive reinforcement.
“Therefore, it is likely that only patients with high level of personal functioning and less severe symptomatology can use these support tools, gaining a positive reinforcement [59, 60]”
From The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: A clinical review (2020) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 11 · Cited by 29
Research works printed but not linked: 10
- Green MF, Horan VP, Lee J. World Psychiatry 2019;18:146-61.
- Radua J, Ramella-Cravaro V, Ioannidis JPA et al. World Psychiatry 2018;17:49-66.
- Toulopoulou T, Picchioni M, Rijsdijk F et al. Arch Gen Psychiatry 2007;64:1348-55.
- McIntosh AM, Gow A, Luciano M et al. Biol Psychiatry 2013;73:938-43.
- Riglin L, Collishaw S, Richards A et al. Lancet Psychiatry 2017;4:57-62.
- Hubbard L, Tansey KE, Rai D et al. Schizophr Bull 2016;42:832-42.
- Weiser M, Reichenberg A, Rabinowitz J et al. Acta Psychiatr Scand 2004;110:471-5.
- McGrath JJ, Saha S, Al-Hamzawi A et al. JAMA Psychiatry 2015;72:697-705.
- Reichenberg A, Harvey PD. Psychol Bull 2007; 133:833-58.
- Saha S, Chant D, Welham J et al. PLoS Med 2005; 2:e141. DOI:10.1002/wps.20644
- Authors
- Reichenberg, A., Velthorst, E., & Davidson, M.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- University of Nicosia (CY)
- Venue
- World Psychiatry
- Publisher
- Wiley
- Published
- 2019-05-06
- Volume
- 18
- Issue
- 2
- Pages
- 162-163
- ISSN
- 1723-8617 (ISSN-L)
- 2051-5545
- PMC
- PMC6502409
- OpenAlex
- W2944186313
- Cited by
- 29
- References
- 11
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 5 · 2022: 5 · 2021: 10 · 2020: 6
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- World Psychiatry (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- schizophrenia, cognitive impairment, psychosis, genetic correlation, polygenic risk score, schizophrenia risk genes, IQ, working memory, cardiovascular comorbidity, environmental risk factors, pregnancy complications, childhood trauma, genetic and environmental factors, cognitive domain, neurodegeneration, neuroinflammation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review